Published in Bioorg Med Chem on November 10, 2009
The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal (2012) 1.64
System xc⁻ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol (2012) 1.27
Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling. Pharmacol Rev (2012) 1.21
Main path and byways: non-vesicular glutamate release by system xc (-) as an important modifier of glutamatergic neurotransmission. J Neurochem (2015) 0.85
Ethyl 5-(4-amino-phen-yl)isoxazole-3-carboxyl-ate. Acta Crystallogr Sect E Struct Rep Online (2012) 0.80
Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-). Bioorg Med Chem Lett (2011) 0.80
Sulfasalazine for brain cancer fits. Expert Opin Investig Drugs (2012) 0.80
Suzuki-Miyaura Cross-Coupling of Benzylic Bromides Under Microwave Conditions. Tetrahedron Lett (2011) 0.79
High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells. PLoS One (2015) 0.77
Microwave accelerated synthesis of isoxazole hydrazide inhibitors of the system xc- transporter: Initial homology model. Bioorg Med Chem Lett (2013) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci (2003) 4.63
The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci (2002) 3.40
Glioma cells release excitotoxic concentrations of glutamate. Cancer Res (1999) 2.34
Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci (2005) 2.17
Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J Biol Chem (1986) 2.11
Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci (1999) 1.94
Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci (2006) 1.85
Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology (2004) 1.68
Overexpression of a glutamate receptor (GluR2) ligand binding domain in Escherichia coli: application of a novel protein folding screen. Proc Natl Acad Sci U S A (1997) 1.58
Ligands for glutamate receptors: design and therapeutic prospects. J Med Chem (2000) 1.58
Calcium-dependent and -independent release of glutamate from synaptosomes monitored by continuous fluorometry. J Neurochem (1987) 1.58
A role for glutamate in growth and invasion of primary brain tumors. J Neurochem (2008) 1.48
Nonvesicular release of glutamate by glial xCT transporters suppresses glutamate receptor clustering in vivo. J Neurosci (2007) 1.20
Aging of glutamate receptors: correlations between binding and spatial memory performance in mice. Mech Ageing Dev (1998) 1.16
The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology (2005) 1.08
Comparison of Na+-dependent glutamate transport activity in synaptosomes, C6 glioma, and Xenopus oocytes expressing excitatory amino acid carrier 1 (EAAC1). Mol Pharmacol (1996) 0.99
Extracellular glutamate levels are chronically elevated in the brains of LP-BM5-infected mice: a mechanism of retrovirus-induced encephalopathy. J Neurochem (1998) 0.99
Uptake of glutamate and cysteine in C-6 glioma cells and in cultured astrocytes. J Neurochem (1990) 0.97
Enhancement of L-cystine transport activity and its relation to xCT gene induction at the blood-brain barrier by diethyl maleate treatment. J Pharmacol Exp Ther (2002) 0.97
HIV-1 gp120 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid. FEBS Lett (1997) 0.95
Utilization of cysteine and cysteine precursors for the synthesis of glutathione in astroglial cultures: preference for cystine. Glia (1998) 0.91
4-amino-5-substituted-3(2H)-pyridazinones as orally active antinociceptive agents: synthesis and studies on the mechanism of action. J Med Chem (2007) 0.89
Synthesis and preliminary pharmacological evaluation of novel derivatives of L-beta-threo-benzylaspartate as inhibitors of the neuronal glutamate transporter EAAT3. Bioorg Med Chem (2008) 0.88
The Lathyrus excitotoxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid is a substrate of the L-cystine/L-glutamate exchanger system xc-. Toxicol Appl Pharmacol (2004) 0.86
Catalytic asymmetric synthesis of glutamate analogues. Org Lett (2004) 0.85
[New derivatives of the isoxazolo-(3,4-d)-pyridazin-7-one system]. Farmaco Sci (1969) 0.84
High affinity transport of taurine and beta-alanine and low affinity transport of gamma-aminobutyric acid by a single transport system in cultured glioma cells. J Biol Chem (1979) 0.84
4-Amino-5-vinyl-3(2H)-pyridazinones and analogues as potent antinociceptive agents: Synthesis, SARs, and preliminary studies on the mechanism of action. Bioorg Med Chem (2007) 0.84
Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. J Med Chem (1999) 0.83
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem (1997) 0.83
Isoxazolo[3,4-d]pyridazinones and analogues as Leishmania mexicana PDE inhibitors. Farmaco (2002) 0.80
Isoxazolo-[3,4-d]-pyridazin-7-(6H)-ones and their corresponding 4,5-disubstituted-3-(2H)-pyridazinone analogues as new substrates for alpha1-adrenoceptor selective antagonists: synthesis, modeling, and binding studies. Bioorg Med Chem (1998) 0.79
The catalytic asymmetric addition of alkyl- and aryl-zinc reagents to an isoxazole aldehyde. Tetrahedron Lett (2008) 0.77
4-Amino-3(2H)-pyridazinones bearing arylpiperazinylalkyl groups and related compounds: synthesis and antinociceptive activity. Farmaco (2003) 0.77
Ionotropic excitatory amino acid receptor ligands. Synthesis and pharmacology of a new amino acid AMPA antagonist. Eur J Med Chem (2000) 0.77
The nature of halogen...halogen synthons: crystallographic and theoretical studies. Chemistry (2006) 3.41
Design, synthesis and biological evaluation of a novel class of anticancer agents: anthracenylisoxazole lexitropsin conjugates. Bioorg Med Chem (2008) 1.71
Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology (2004) 1.68
Using behavior analysis to examine the outcomes of unproven therapies: an evaluation of hyperbaric oxygen therapy for children with autism. Behav Anal Pract (2008) 1.59
New roles for 1,1-diamino-2,2-dinitroethene (FOX-7): halogenated FOX-7 and azo-bis(diahaloFOX) as energetic materials and oxidizers. J Am Chem Soc (2013) 1.37
Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models. Basic Res Cardiol (2011) 1.36
Energetic nitrogen-rich derivatives of 1,5-diaminotetrazole. Angew Chem Int Ed Engl (2008) 1.30
System xc⁻ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol (2012) 1.27
The nature of halogen...halide synthons: theoretical and crystallographic studies. J Phys Chem A (2007) 1.21
Inhibitor of the glutamate vesicular transporter (VGLUT). Curr Med Chem (2005) 1.12
Bis-anthracenyl isoxazolyl amides have enhanced anticancer activity. Bioorg Med Chem Lett (2009) 1.11
Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport. J Med Chem (2002) 1.11
Unique structure-activity relationship for 4-isoxazolyl-1,4-dihydropyridines. J Med Chem (2003) 1.10
The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology (2005) 1.08
ZnTe6O13, a new ZnO-TeO2 phase. Acta Crystallogr C (2007) 1.07
Can selective ligands for glutamate binding proteins be rationally designed? Curr Top Med Chem (2006) 1.02
Anti-inflammatory influences on behavioral, but not cortisol, responses during maternal separation. Psychoneuroendocrinology (2009) 1.01
Polyazidopyrimidines: high-energy compounds and precursors to carbon nanotubes. Angew Chem Int Ed Engl (2006) 1.00
Straightforward syntheses of hypervalent iodine(III) reagents mediated by Selectfluor. Org Lett (2005) 0.98
Structure and magnetism of a spin ladder system: (C5H9NH3)2CuBr4. Inorg Chem (2004) 0.98
Asymmetric catalytic Strecker reaction of N-phosphonyl imines with Et2AlCN using amino alcohols and BINOLs as catalysts. Chem Commun (Camb) (2010) 0.94
Asymmetric catalytic N-phosphonyl imine chemistry: the use of primary free amino acids and Et2AlCN for asymmetric catalytic Strecker reaction. J Org Chem (2010) 0.92
High-capacity gold nanoparticle functionalised polymer monoliths. Chem Commun (Camb) (2010) 0.92
Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1. J Med Chem (2005) 0.92
Synthesis of pentafluorosulfanylpyrazole and pentafluorosulfanyl-1,2,3-triazole and their derivatives as energetic materials by click chemistry. Org Lett (2007) 0.91
Synthetic Utility of Epoxides for Chiral Functionalization of Isoxazoles. Tetrahedron Lett (2008) 0.91
Pipette-tip selective extraction of glycoproteins with lectin modified gold nano-particles on a polymer monolithic phase. Analyst (2011) 0.89
An ionic liquid-coordinated palladium complex: a highly efficient and recyclable catalyst for the Heck reaction. Org Lett (2004) 0.89
Dimethylammonium trichlorocuprate(II): structural transition, low-temperature crystal structure, and unusual two-magnetic chain structure dictated by nonbonding chloride-chloride contacts. Inorg Chem (2006) 0.89
Retinal artery occlusion: visual outcome after treatment with hyperbaric oxygen. Diving Hyperb Med (2011) 0.88
Synthesis and preliminary pharmacological evaluation of novel derivatives of L-beta-threo-benzylaspartate as inhibitors of the neuronal glutamate transporter EAAT3. Bioorg Med Chem (2008) 0.88
2,4,5-trinitroimidazole-based energetic salts. Chemistry (2007) 0.87
Multicomponent reactions for the synthesis of heterocycles. Chem Asian J (2010) 0.87
The first (ferrocenylmethyl)imidazolium and (ferrocenylmethyl)triazolium room temperature ionic liquids. Inorg Chem (2004) 0.87
Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder. Addict Behav (2013) 0.87
Maternal separation produces, and a second separation enhances, core temperature and passive behavioral responses in guinea pig pups. Physiol Behav (2010) 0.86
The Lathyrus excitotoxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid is a substrate of the L-cystine/L-glutamate exchanger system xc-. Toxicol Appl Pharmacol (2004) 0.86
Molecular characterisation of resistance to ALS-inhibiting herbicides in Hordeum leporinum biotypes. Pest Manag Sci (2007) 0.85
Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x(c)(-) over the vesicular glutamate transporter. Bioorg Med Chem Lett (2009) 0.85
Catalytic asymmetric synthesis of glutamate analogues. Org Lett (2004) 0.85
Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr Top Med Chem (2010) 0.85
Energetic quaternary salts containing bi(1,2,4-triazoles). Inorg Chem (2005) 0.84
Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA. J Med Chem (2005) 0.84
Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol (2011) 0.84
Mechanistic insights into catalytic h(2) oxidation by ni complexes containing a diphosphine ligand with a positioned amine base. J Am Chem Soc (2009) 0.84
Carbonyl and oxalyl bridged bis(1,5-diaminotetrazole)-based energetic salts. Chemistry (2009) 0.83
A theoretical and experimental scale of aromaticity. The first nucleus-independent chemical shifts (NICS) study of the dimethyldihydropyrene nucleus. J Am Chem Soc (2002) 0.83
Metal-assisted in situ formation of a tridentate acetylacetone ligand for complexation of fac-Re(CO)3+ for radiopharmaceutical applications. Inorg Chem (2008) 0.83
Tetrapeptide inhibitors of the glutamate vesicular transporter (VGLUT). Bioorg Med Chem Lett (2007) 0.83
Pd-catalyzed arylation of silyl enol ethers of substituted alpha-fluoroketones. Org Biomol Chem (2009) 0.83
Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies. J Med Chem (2008) 0.82
Synthesis and characterization of nonsteroidal-linked M(CO)(3)+ (M = 99mTc, Re) compounds based on the androgen receptor targeting molecule flutamide. Bioconjug Chem (2009) 0.82
Energetic salts from N-aminoazoles. Inorg Chem (2004) 0.81
Investigation of the coordination interactions of S-(pyridin-2-ylmethyl)-L-cysteine ligands with M(CO)(3)(+) (M = Re, (99m)Tc). Inorg Chem (2009) 0.81
Energetic bicyclic azolium salts. Chemistry (2006) 0.81
Uncompetitive antagonism of AMPA receptors: Mechanistic insights from studies of polyamine toxin derivatives. J Med Chem (2006) 0.80
Sulfasalazine for brain cancer fits. Expert Opin Investig Drugs (2012) 0.80
Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni'). Drug Test Anal (2014) 0.80
The role of the second coordination sphere of [Ni(PCy2NBz2)2](BF4)2 in reversible carbon monoxide binding. J Am Chem Soc (2007) 0.80
Hypergolic ionic liquids with the 2,2-dialkyltriazanium cation. Angew Chem Int Ed Engl (2009) 0.80
Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-). Bioorg Med Chem Lett (2011) 0.80
Regional distribution of sodium-dependent excitatory amino acid transporters in rat spinal cord. J Spinal Cord Med (2007) 0.80
Suzuki-Miyaura Cross-Coupling of Benzylic Bromides Under Microwave Conditions. Tetrahedron Lett (2011) 0.79
Increased excitatory amino acid transport into murine prion protein knockout astrocytes cultured in vitro. Glia (2011) 0.79
Preparation of ultrafine chalcopyrite nanoparticles via the photochemical decomposition of molecular single-source precursors. Nano Lett (2006) 0.79
Synthesis and anti-acetylcholinesterase properties of novel β- and γ-substituted alkoxy organophosphonates. Bioorg Med Chem Lett (2013) 0.79
3-Amino-6-nitroamino-tetrazine (ANAT)-based energetic salts. Chem Commun (Camb) (2006) 0.78
Heterocyclic-based nitrodicyanomethanide and dinitrocyanomethanide salts: a family of new energetic ionic liquids. Inorg Chem (2007) 0.78
Furazan-functionalized tetrazolate-based salts: a new family of insensitive energetic materials. Chemistry (2009) 0.78
Functional expression, purification and high sequence coverage mass spectrometric characterization of human excitatory amino acid transporter EAAT2. Protein Expr Purif (2010) 0.78
Energetic nitrogen-rich Cu(II) and Cd(II) 5,5'-azobis(tetrazolate) complexes. Inorg Chem (2009) 0.78
Diagnosing social anxiety disorder in the presence of obesity: implications for a proposed change in DSM-5. Depress Anxiety (2011) 0.78
Asymmetric hydrophosphylation of chiral N-phosphonyl imines provides an efficient approach to chiral α-amino phosphonates. Chem Biol Drug Des (2010) 0.78
Efficient Heck reactions catalyzed by a highly recyclable palladium(II) complex of a pyridyl-functionalized imidazolium-based ionic liquid. Org Biomol Chem (2007) 0.78
The synthesis of di(aminoguanidine) 5-nitroiminotetrazolate: some diprotic or monoprotic acids as precursors of energetic salts. Chemistry (2008) 0.77
Lanthanide complexes of the Kläui metalloligand, CpCo(P═O(OR)2)3: an examination of ligand exchange kinetics between isotopomers by electrospray mass spectrometry. Inorg Chem (2012) 0.77
Reduction of oxygen catalyzed by nickel diphosphine complexes with positioned pendant amines. Dalton Trans (2010) 0.77
Photo-initiated thiol-ene click reactions as a potential strategy for incorporation of [M(I)(CO)3]+ (M = Re, (99m)Tc) complexes. Inorg Chem (2013) 0.77
The catalytic asymmetric addition of alkyl- and aryl-zinc reagents to an isoxazole aldehyde. Tetrahedron Lett (2008) 0.77
Ethyl 4-{1-[(2,4-dinitro-phen-yl)hydrazono]eth-yl}-5-(2-naphthyl-methoxy-meth-yl)isoxazole-3-carboxyl-ate. Acta Crystallogr Sect E Struct Rep Online (2008) 0.77
Crystal structure and magnetism of a well isolated 2D-quantum Heisenberg antiferromagnet, (Quinolinium)(2)CuBr(4).2H(2)O, and its anhydrous form. Inorg Chem (2010) 0.77
13-methyl-2,6-dithia[7]metacyclophane: a useful molecule to connect VT NMR results and structure with calculations. J Org Chem (2005) 0.76
Time in Bed is Associated with Decreased Physical Activity and Higher BMI in Women Seeking Weight Loss Treatment. ISRN Obes (2012) 0.76
Treatment for comorbid borderline personality disorder and alcohol use disorders: a review of the evidence and future recommendations. Exp Clin Psychopharmacol (2012) 0.76
The pain explanation and treatment diagram: a tool to enhance patient self-management of persistent pain. PM R (2012) 0.76
Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J Nerv Ment Dis (2011) 0.76
Strong H...F hydrogen bonds as synthons in polymeric quantum magnets: structural, magnetic, and theoretical characterization of [Cu(HF2)(pyrazine)2]SbF6, [Cu2F(HF)(HF2)(pyrazine)4](SbF6)2, and [CuAg(H3F4)(pyrazine)5](SbF6)2. J Am Chem Soc (2009) 0.75
Synthesis and biological characterization of protease-activated prodrugs of doxazolidine. J Med Chem (2012) 0.75
trans-K(3)[TcO(2)(CN)(4)]. Acta Crystallogr Sect E Struct Rep Online (2010) 0.75